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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYHumanembryonic stemcell (hESC)-derivedpancreaticprogenitorcells effectively reversehyperglycemia in rodentmodelsof type1diabetes,
but their capacity to treat type2 diabetes hasnot been reported. An immunodeficientmodel of type2diabeteswas generated byhigh-fat diet
(HFD) feeding in SCID-beige mice. Exposure to HFDs did not impact the maturation of macroencapsulated pancreatic progenitor cells
into glucose-responsive insulin-secreting cells following transplantation, and the cell therapy improved glucose tolerance in HFD-fed
transplant recipients after 24 weeks. However, since diet-induced hyperglycemia and obesity were not fully ameliorated by transplantation
alone, a second cohort of HFD-fed mice was treated with pancreatic progenitor cells combined with one of three antidiabetic drugs. All
combination therapies rapidly improved body weight and co-treatment with either sitagliptin or metformin improved hyperglycemia
after only 12weeks. Therefore, a stem cell-based therapymay be effective for treating type 2 diabetes, particularly in combinationwith anti-
diabetic drugs.INTRODUCTION
The International Diabetes Federation estimates that up
to 95% of the 380 million people worldwide who are
affected by diabetes suffer from type 2 diabetes (Interna-
tional Diabetes Federation, 2014). Thus, the potential
impact of a novel treatment for type 2 diabetes is enor-
mous. Despite obvious differences in the pathogenesis of
type 1 and 2 diabetes, both diseases are characterized by
impaired glucose homeostasis resulting from insufficient
insulin production by pancreatic beta cells. In type 1 dia-
betes, beta cell destruction by the immune system is rapid
and extensive, causing severe insulin deficiency. In con-
trast, beta cell failure in type 2 diabetes occurs gradually
over time and is associated with peripheral insulin resis-
tance. Clinical studies have shown that patients with
type 2 diabetes also have reduced beta cell mass (Butler
et al., 2003; Yoon et al., 2003) and declining beta cell func-
tion during the progression from pre-diabetes to overt dia-
betes (Weyer et al., 1999; Ferrannini et al., 2005). Therefore,
treatment strategies for type 2 diabetes should be aimed at
restoring beta cell mass and/or function, in addition to
improving insulin sensitivity (Halban, 2008; Kahn et al.,
2014).
Transplantation of cadaveric human islets can restore
insulin-independence in patients with type 1 diabetes
(Shapiro et al., 2000; Ryan et al., 2001), but this approach
has not been actively pursued for type 2 diabetes, likelyStemdue to the inadequate supply of donor islets, risk of immu-
nosuppression, and perceived hurdle of insulin resistance.
The obstacle of an insufficient cell supply may be over-
come with the use of human embryonic stem cells
(hESCs). We previously demonstrated that hESC-derived
pancreatic progenitor cells reversed hyperglycemia in a
mouse model of type 1 diabetes characterized by severe
beta cell destruction and insulin deficiency (Rezania
et al., 2012, 2013; Bruin et al., 2013). However, the efficacy
of this stem cell-based therapy for treating hyperglycemia
in an obesogenic and insulin-resistant environment, such
as in type 2 diabetes, has not been reported. Based on
evidence that intensive insulin therapy improves insulin
sensitivity, glycemic control, and beta cell function in
patients with type 2 diabetes (Weng et al., 2008; Kramer
et al., 2013), we hypothesized that hESC-derived insulin-
secreting cells may also be effective for this patient
population.
Our first aim was to establish a model of type 2 diabetes
in immunodeficient mice that would be compatible with
xenotransplantation. Different strains of rodents have
widely variable susceptibility to high-fat diet (HFD)-
induced obesity and/or hyperglycemia (Srinivasan and
Ramarao, 2007; Svenson et al., 2007; Hariri and Thibault,
2010). Moreover, insulin resistance, a hallmark feature of
type 2 diabetes (Kahn et al., 2006), is thought to be driven
primarily by obesity-associated inflammation (reviewed in
Kalupahana et al., 2012; Osborn and Olefsky, 2012), andCell Reports j Vol. 4 j 605–620 j April 14, 2015 j ª2015 The Authors 605
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Figure 1. SCID-Beige Mice Rapidly Develop Obesity, Fasting Hyperglycemia, Glucose Intolerance, and Insulin Resistance Following
Exposure to HFDs
(A and B) Body weight (A) and fasting blood glucose levels (B) were measured during a 14-day acclimation period on normal chow and
for 51 days following administration of one of the following diets: 10% fat (black; n = 11 mice), 45% fat (red; n = 11 mice), 60% fat (blue;
n = 11 mice), or Western diet (green; n = 11 mice).
(C and D) Blood glucose (C, raw values and area under the curve) and plasma mouse insulin levels (D) were assessed during an oral glucose
tolerance test (OGTT; n = 4–6 mice per group) on day 47. See Figure S1 for OGTTs at days 5 and 32.
(E) An insulin tolerance test (ITT) was performed on day 42 (n = 9–11 mice per group). Glucose levels are presented as a percentage of basal
glucose levels (at time 0) and the area above the curve was calculated using 100% as the baseline.
(F) Adiposity (% fat) was assessed by DEXA at day 43 in a subset of mice (n = 3 mice per group).
(legend continued on next page)
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recruitment of T cells (Feuerer et al., 2009; Nishimura et al.,
2009; Winer et al., 2009) and B cells (Winer et al., 2011) to
insulin-sensitive tissues. SCID-beige mice are a sponta-
neous double-mutantmodel inwhich the scidmutation re-
sults in a lack of both T and B lymphocytes, and the beige
mutation causes defects in cytotoxic T cells, macrophages,
and NK cells (http://www.taconic.com). To our knowledge,
the susceptibility of double-mutant SCID-beige mice to
HFDs has not previously been examined as a potential
model of type 2 diabetes.
An important consideration in translating a stem cell-
derived pancreatic progenitor therapy to clinical practice
is the variability that will be encountered within the pa-
tient environment during the period of cell engraftment
and maturation in vivo. This is particularly relevant given
that macroencapsulated hESC-derived pancreatic pro-
genitor cells are now being tested for safety, tolerability,
and efficacy in a phase 1/2 clinical trial by Viacyte
(ClinicalTrials.gov, Identifier: NCT02239354). We hypoth-
esized that exposure to HFDs may impair the development
of hESC-derived insulin-secreting cells, since obesity-asso-
ciated lipotoxicity and inflammation contribute to beta
cell dysfunction in patients with type 2 diabetes (reviewed
in Potter et al., 2014). Furthermore, both human and
rodent islets displayed beta cell dysfunction following
transplant into HFD-fed rodents (Hiramatsu and Grill,
2001; Gargani et al., 2013). Here, we examined the impact
of HFDs on hESC-derived progenitor cell development
in vivo, and assessed whether a stem cell-based insulin
therapy could improve glycemic control in mice with
diet-induced obesity, insulin resistance, and hyperglyce-
mia. We also investigated the efficacy of combining the
cell therapywith one of three antidiabetic drugs: sitagliptin
(a dipeptidyl peptidase-4 [DPP4 inhibitor]), metformin
(suppresses hepatic gluconeogenesis and enhances insulin
sensitivity), and rosiglitazone (a PPARg agonist from the
thiazolidinedione [TZD] class). Our studies demonstrated
that a combination therapy was more effective in HFD-
fed mice than either antidiabetic drugs or progenitor cell
transplants alone. Moreover, neither HFDs nor antidiabetic
drugs impacted the ability of hESC-derived cells to mature
in vivo and appropriately secrete insulin in response to
glucose.(G) Mouse leptin levels were measured on days 47–49 following a 4-
concentration in the leptin assay). See Figures S1E–S1G for circulatin
(H) Immunofluorescent staining of epididymal fat from immunocom
36 weeks, and from an immunocompetent adult ob/ob mouse. F4/
respectively. Crown-like structures, representing macrophage infiltrat
(A–C and E–G) *p < 0.05 versus 10% controls (two-way ANOVA for com
for bar graphs); (D) *p < 0.05 versus time 0 (one-way ANOVA). Data a
plots with individual mice shown as separate data points.
See also Figure S6 and Table S2.
StemRESULTS
SCID-Beige Mice Rapidly Developed Diet-Induced
Obesity, Insulin Resistance, and Hyperglycemia
All three of the HFDs used in this study (45% fat, 60% fat,
andWestern) induced rapid increases in fastingbodyweight
(BW; Figure 1A) and blood glucose levels (Figure 1B)
compared with low-fat diet (LFD) controls (10% fat). More-
over, after only 5 days, mice in all three HFD groups were
severely glucose intolerant relative to LFD controls (Fig-
ure S1A), even though no differences in BW were observed
at that time (Figure S1B). At 32 days, HFD mice were both
glucose intolerant (Figure S1C) and significantly heavier
(Figure S1D) than LFD controls. Mice fed 45% and 60% fat
diets were overtly insulin resistant at day 42 (higher glucose
levels at 10 and 60–120 min post-insulin, and reduced area
above the curve relative to LFD controls), whereas mice on
theWestern diet only showed significant insulin resistance
at 10 min after insulin administration (Figure 1E).
In the week preceding transplantation (day 51), mice in
all HFD groups were glucose intolerant (day 47, Figure 1C)
and showed insulin-secretion kinetics that differed from
LFD controls (either no glucose-induced insulin secretion
or altered timing of peak insulin levels; Figure 1D). All
HFD mice were significantly overweight (Figure 1A) and
had increased adiposity (Figure 1F) compared with LFD
controls, andmice fed 45% or 60% fat diets also had signif-
icantly elevated circulating leptin levels (Figure 1G). Expo-
sure to HFDs caused dyslipidemia, including significantly
reduced plasma free fatty acid levels in all HFD-fed mice
(Figure S1E), reduced triglyceride levels in 45% and 60%
fat groups (Figure S1F), and elevated cholesterol levels in
the Western-diet group compared with LFD controls (Fig-
ure S1G). Interestingly, the HFD-induced metabolic defects
in immunodeficient mice were not associated with macro-
phage infiltration in adipose tissue (marked by F4/80
immunoreactivity; Weisberg et al., 2003), whereas signifi-
cant accumulation of F4/80-positive crown-like structures
was observed in the epididymal fat of ob/ob mice, an
immunocompetent model of type 2 diabetes (Figure 1H).
Fibroblast growth factor 21 (FGF21) was used as an adipo-
cyte marker because it is highly expressed in white adipose
tissue (Markan et al., 2014).to 6-hr morning fast (dashed line indicates the highest standard
g lipid levels.
promised SCID-beige mice fed either a 10% or 60% fat diet for
80 and FGF21 are shown as macrophage and adipocyte markers,
ion, are shown in insets. Scale bars, 200 mm.
parison of multiple time points in line graphs, and one-way ANOVA
re represented as mean ± SEM (line graphs) or as box-and-whisker
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Taken together, these results indicate that 7 weeks of
exposure to HFDs generated a type 2-like diabetes model
characterized by hyperglycemia, insulin resistance, obesity,
and dyslipidemia in immunodeficient mice. Given the
phenotypic similarities between mice on the 45% and
60% fat diets, these groups were combined for all further
analysis (hereafter referred to as the 45%–60% fat group).
Exposure to HFDs Did Not Affect the Function of
hESC-Derived Endocrine Cells In Vivo
Prior to transplantation, differentiated hESC-derived
pancreatic progenitor cells were assessed by fluorescence-
activated cell sorting (FACS) and immunofluorescent stain-
ing (Figure S2). Following in vitro differentiation, 95% of
cells expressed PDX1 and65% expressed NKX6.1 (Figures
S2A, S2C, S2D, and S2G), two key markers of pancreatic
endoderm. Approximately 20% of PDX1-positive cells
were in the cell cycle, as indicated by Ki67 or PCNA expres-
sion (Figures S2A and S2D), and the pluripotency marker
OCT3/4 was not detected (Figure S2A). Although 14%
of progenitor cells expressed endocrine markers (Figures
S2A and S2B), only 2.5% of synaptophysin-positive cells
co-expressed NKX6.1 (Figure S2A) and most were polyhor-
monal (Figure S2F), indicative of an immature endocrine
population. Indeed, insulin/C-peptide-positive cells only
rarely co-expressed PAX6 (Figure S2E) or NKX6.1 (Fig-
ure S2C) at this stage of differentiation. These data are
consistent with the characteristics of hESC-derived pancre-
atic progenitor cells described previously by our group
(Rezania et al., 2012, 2013; Bruin et al., 2013).
Progenitor cells were encapsulated in Theracyte devices
and transplanted subcutaneously into immunodeficient
mice fromeachof the four diet regimens.Weused immuno-
deficient mice because although macroencapsulation de-
vices are predicted to protect human cells from allogeneic
immune rejection (Tibell et al., 2001), they are unlikely to
protect them from xenograft rejection (Brauker et al.,
1996; Mckenzie et al., 2001). The immunoisolation devices
allowed us to mimic studies in patients receiving macro-
encapsulated pancreatic progenitor cells (ClinicalTrials.
gov, Identifier: NCT02239354). Following transplantation,
hESC-derived cells from all diet groups secreted similar
levels of human C-peptide under basal and fed conditions
between 8 and 20 weeks (Figure 2A), and produced robust
glucose-stimulated human C-peptide secretion at 18 weeks
(Figures 2B and 2C). Similarly, human insulin secretionwas
induced by an arginine challenge in all diet groups at
24 weeks, although due to high variability, the Western-
diet group did not reach statistical significance (Figure 2D).
We observed a trend toward increased basal glucagon secre-
tion in the HFD groups, but as four out of five mice in the
LFD group had undetectable fasting glucagon levels, it
was not possible to perform a statistical analysis (Figure 2E).608 Stem Cell Reports j Vol. 4 j 605–620 j April 14, 2015 j ª2015 The AuthoArginine-stimulated glucagon levels were similar between
diet groups (Figures 2E and 2F), and we estimate that
approximately half of the circulating glucagon may have
originated from hESC-derived cells, as indicated by the dif-
ference between glucagon levels in sham-treated mice and
transplant recipients (Tx; Figure 2F).
hESC-Derived Endocrine Cells Were Similar following
LFD or HFD Exposure, but Grafts from HFD-Fed Mice
Contained More Polyhormonal Cells
At 29 weeks post-transplantation, hESC-derived grafts had
similar or significantly higher levels of islet-related genes
compared with human islets and there were no significant
differences between grafts from mice fed LFDs or HFDs
(Figure 3). The majority of cells within the harvested de-
vices were immunoreactive for the endocrine marker syn-
aptophysin, and a small proportion expressed the ductal
marker CK19. Trypsin-positive exocrine cells were rarely
observed (Figure 4A). The grafts were largely composed
of cells expressing insulin, glucagon, or somatostatin (Fig-
ures 4B and 4E), and the percentage of mono-hormonal
insulin-positive and glucagon-positive cells was similar
between diet groups (Figure 4C). However, we did note
a minor but significantly higher percentage of cells that
were immunoreactive for both insulin and glucagon
in the HFD grafts compared with LFD grafts (Figures 4C
and 4D). Aside from these rare polyhormonal cells, expo-
sure to HFDs did not appear to generally influence the
maturation state of hESC-derived insulin-secreting cells:
the majority of insulin-positive cells in all transplant
recipients co-expressed PDX1 (Figure 4F), NKX2.2 (Fig-
ure 4G), NKX6.1 (Figure 4H), and MAFA (Figure 4I) at
29 weeks post-transplantation.
hESC-Derived Insulin-Secreting Cells Improved Diet-
Induced Dysglycemia and Insulin Resistance
Long-term tracking revealed that mice in all HFD groups
continued to be overweight (Figure S3A) and hyperglyce-
mic under fasting conditions (Figure S3E) compared with
LFD controls throughout the duration of the study. Trans-
plantation of hESC-derived cells did not affect either BW
(Figures S3B–S3D) or fasting blood glucose levels (Figures
S3F–S3H) compared with sham surgery. However, we did
observe significant improvements in long-term glycemic
control, as measured by HbA1C, following transplantation
(Figures 5A and 5B). HbA1C levels were elevated at 12 and
24 weeks in all HFD sham mice compared with LFD sham
controls, andwere significantly reduced by transplantation
in the 45%–60% fat group at both ages (Figures 5A and 5B).
Transplant recipients on 45%–60% fat diets also displayed a
significantly lower glucose excursion following a mixed-
meal stimulus compared with sham mice at 20 weeks
(Figure 5C), and all HFD transplant recipients hadrs
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Figure 2. Exposure to HFDs Does Not Affect the Function of hESC-Derived Pancreatic Endocrine Cells In Vivo
The development of hESC-derived progenitor cells into pancreatic endocrine cells was assessed in mice fed a 10% fat (black), 45% or 60%
fat (purple), or Western (green) diet. See Figure S2 for characterization of the progenitor cells pre-transplantation.
(A) Human C-peptide levels were measured after an overnight fast and 40 min following an oral mixed-meal challenge (‘‘fed’’) at 8, 12, 16,
and 20 weeks post-transplantation. *p < 0.05, paired t test (fast versus fed).
(B and C) At 18 weeks post-transplantation, human C-peptide levels were measured during an i.p. glucose tolerance test (ipGTT). In (B)
data are normalized to baseline levels, and in (C) raw levels (ng/ml) are presented for individual animals, with each diet group shown on a
separate plot. *p < 0.05, one-way repeated-measures ANOVA (versus time 0).
(D–F) At 24 weeks post-transplantation, an i.p. arginine tolerance test (ipArgTT) was performed. Plasma was collected after a 4-hr fast and
15 min following arginine administration to measure human insulin (D) and glucagon (E and F) levels. (E) shows glucagon levels at 0 and 15
minutes in transplant recipients, and (F) shows glucagon levels in sham-treatedmice (Sham, striped bars) and transplant recipients (Tx, solid
bars) at 15minutes only. The red line indicates the lower limit of detection for the glucagon assay. (D and E) *p < 0.05, one-tailed paired t test
(0 versus 15 min); (F) *p < 0.05, two-tailed t test (sham versus Tx). Data points from individual mice are shown as box-and-whisker plots.
See also Table S2.significantly improved glucose tolerance at 24 weeks post-
transplantation (Figures 5E and S4B). These improvements
were not yet evident at 18 weeks (Figures 5D and S4A).
Glucose tolerance in the 45%–60% fat group was notStemcompletely ameliorated at 24 weeks, but the area under
the curve for transplant recipients in the Western group
was indistinguishable from that obtained for controls (Fig-
ures 5E and S4B). Interestingly, we also observed a modestCell Reports j Vol. 4 j 605–620 j April 14, 2015 j ª2015 The Authors 609
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Figure 3. Gene Expression Profiles Are Similar for hESC-Derived Graft Tissues Exposed to Different LFDs or HFDs In Vivo
The gene expression of islet-related genes was assessed in macroencapsulated hESC-derived grafts at 29 weeks post-transplantation from
mice fed a LFD (10% fat) or HFD (45% fat, 60% fat, and Western), as well as in adult human islet preparations. All data are presented as the
fold change relative to undifferentiated hESCs (H1 cells) using a log scale. Data points from individual mice or different human islet donors
are shown as box-and-whisker plots. *p < 0.05 for hESC-derived grafts from each diet group versus human islets (one-way ANOVA). See also
Tables S2 and S3.but statistically significant improvement in insulin sensi-
tivity at 22 weeks in transplanted HFD-fed mice compared
with shams (Figures 5F, S4C, and S4D), which may have
contributed to the improved glucose tolerance in HFD
transplant recipients (Figure 5E).
We assessed beta and alpha cell mass in the endogenous
pancreas from mice fed 10% or 60% fat diets to determine
whether the improved glucose tolerance in HFD-fed trans-
plant recipients could be accounted for by expansion of the
endogenous endocrine pancreas. Beta cell mass was signif-610 Stem Cell Reports j Vol. 4 j 605–620 j April 14, 2015 j ª2015 The Authoicantly higher in all mice on 60% fat diets compared with
LFD sham controls, and there was no difference between
sham and transplanted mice in either diet group (Figures
S5A and S5D). Interestingly, there was no effect of HFDs
on alpha cell mass, but a significant reduction in alpha
cell mass was observed in LFD transplant recipients
compared with LFD shams (Figures S5B and S5D). There
were no significant differences in the ratio of insulin-posi-
tive to glucagon-positive area in the pancreas of mice on
either diet (Figure S5C).rs
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Figure 4. The Morphology of Macroencapsulated hESC-Derived Pancreatic Endocrine Cells Is Similar in Grafts from Mice Fed a LFD
or HFD
(A, B, and D–I) Representative immunofluorescent images of Theracyte devices at 29 weeks post-transplantation from mice fed 10% fat or
60% fat diets.
(A) Themajority of hESC-derived cells within devices fromboth diet groupswere endocrine cells. The expression of synaptophysin (endocrine
marker, red), CK19 (ductal marker, green), trypsin (exocrine marker, blue), and DAPI (nuclear marker, white) is shown. Scale bars, 100 mm.
(B) The endocrine compartment was mainly composed of cells expressing either insulin (red, guinea pig antibody), glucagon (green, rabbit
antibody), or somatostatin (blue, Ms antibody); scale bars, 100 mm. Higher-magnification images are shown in (E); scale bars, 50 mm.
(C) The percentage of cells (% of DAPI+ nuclei) within devices that were immunoreactive for insulin (insulin+), glucagon (glucagon+), or
both hormones (ins+/gcg+) was quantified in grafts from mice fed 10% fat or 45%–60% fat diets. *p < 0.05, two-tailed t test. Data are
represented as mean ± SEM and data points from individual mice are also shown.
(D) Example of graft tissue from the 60% fat diet group with a region of endocrine cells that expressed both insulin and glucagon (white
arrows); scale bars, 25 mm.
(F–I) The majority of insulin-positive cells (INS, red) show a mature beta cell phenotype, including co-expression of key beta cell
transcription factors (green): (F) PDX1, (G) NKX2.2, (H) NKX6.1, and (I) MAFA; scale bars, 50 mm. See also Figure S2 and Tables S2 and S4.Cell Therapy Had No Effect on the Obesity Phenotype,
but Improved Liver Weight in HFD Mice
Although hESC-derived cells improved glucose homeosta-
sis in HFD-fed mice, there was no apparent effect on the
obesity phenotype. At the end of our study (29 weeks
post-transplantation and 36 weeks post-diet), mice on
the 45%–60% fat diets (sham and Tx) had significantlyStemhigher BW, adiposity (epididymal fat pad weight as a
proportion of BW) and circulating leptin levels than LFD
shams (Figures S5E–S5G). The obesity phenotype was
more subtle in Western-diet mice during the first 7 weeks
(Figure 1A) and by the end of the study there were no sig-
nificant differences in BW, adiposity, or leptin levels be-
tween Western-fed mice (sham and Tx) and LFD shamCell Reports j Vol. 4 j 605–620 j April 14, 2015 j ª2015 The Authors 611
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Figure 5. Cell Transplant Recipients on HFDs Show Improved Glucose Homeostasis Compared with Sham-Treated Mice
(A and B) HbA1C levels were measured at 12 (A) and 24 (B) weeks post-transplantation in sham mice (solid bars) and transplant recipients
(Tx, striped bars).
(C) At 20 weeks post-transplantation, blood glucose levels were measured after an overnight fast and 40 min following an oral meal
challenge (‘‘Fed’’).
(D and E) ipGTTs were performed at 18 (D) and 24 (E) weeks post-transplantation in sham mice (solid lines with closed symbols; solid bars)
and transplant recipients (Tx, dashed lines with open symbols; striped bars) on 10% fat (gray; 18 weeks: Tx/Sham, n = 4 mice; 24 weeks: Tx,
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(legend continued on next page)
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controls (Figures S5E–S5G). All HFD groups had signifi-
cantly higher liver weight (Figure S5H) and evidence of
cytoplasmic vacuolation, consistent with dietary lipidosis
in the liver (Figure S5I; Western and 45% fat groups not
shown) compared with LFD controls. Interestingly, trans-
plant recipients fed 45%–60% fat diets had significantly
reduced liver weight relative to shams (Figure S5H),
although a pathology assessment did not reveal differences
in cytoplasmic vacuolation in H&E-stained liver sections
(Figure S5I). Similarly, vacuolation of renal tubular epithe-
lium was observed in kidney sections from all HFD groups
(consistent with dietary lipidosis) and there was no effect
of cell transplantation on this phenotype (data not
shown). Other tissue pathologies (Table S1) were consis-
tent with spontaneous age- and sex-related events and
considered to be unrelated to exposure to diets or cell
transplants (data not shown).
Combined Treatment of HFD-Fed Mice with
Progenitor Cell Transplants and an Antidiabetic Drug
Rapidly Improved Diet-Induced Obesity and Glucose
Intolerance
Since the progenitor cell therapy resulted in improved
glucose tolerance in HFD-fed mice at 24 weeks, but not
full reversal of the diabetes phenotype, we next investi-
gated a combination therapy with known antidiabetic
drugs. A second cohort of SCID-beige mice was placed on
either a LFD (10% fat) or HFD (60% fat) for 6 weeks, fol-
lowed by long-term administration of either sitagliptin
(4 g/kg in 60% fat diet), rosiglitazone (18 mg/kg in 60%
fat diet), or metformin (1.25 mg/ml in drinking water) in
HFD-fed mice (treatment groups are summarized in Table
S2). Similar to our first cohort, SCID-beige mice in this sec-
ond cohort rapidly developed attributes of type 2 diabetes
following HFD administration (Figure S6).
At the time of transplantation (1 week after drug admin-
istration), all HFD-fed mice were significantly heavier than
LFD controls (Figure 6F). Interestingly, weight loss was
observedwithin the first 2 weeks following transplantation
in HFD-fed mice on antidiabetic drugs (Figures 6C–6E). In
contrast, no change in BW was observed during this time
in either HFD transplant recipients without drug treatment
(Figure 6B) or sham mice on any drug (Figures 6A–6E). All
transplant recipients that received antidiabetic drugs had
significantly lower BW on day 75 (Figure 6F) and reducedthe curve (right panel) was calculated using the fasting glucose level (
(GTTs and ITTs) from sham and transplanted mice are shown separatel
the same plots. Data are represented as mean ± SEM (line graphs) or
points. For all box-and-whisker plots: *p < 0.05, one-way ANOVA versus
graphs: *p < 0.05, two-way ANOVA, Tx versus sham. See Figure S3 for l
the effect of cell transplants on endogenous pancreas, liver, fat, and
See also Table S2.
Stemepididymal fat pad weight (relative to BW; Figure 6G)
compared with sham mice, such that neither parameter
was different from LFD-fed sham controls. As in our previ-
ous cohort (Figures S3 and S5E), therewas no effect of trans-
plantation on BW (Figures 6B and 6F) or circulating leptin
levels (Figure 6H) in HFD-fedmice without drug treatment,
although we did observe a reduction in relative epididymal
fat pad weight in this cohort (Figure 6G). Interestingly, the
combination of a cell transplant with either metformin or
sitagliptin resulted in significantly reduced circulating lep-
tin levels in the transplant recipients compared with their
respective sham controls (Figure 6G). The cell therapy
had no effect on restoring leptin levels in the rosiglitazone
group (Figure 6G).
Fasting blood glucose levels were not affected by any of
the combination therapies throughout the study duration
(Figure S7). At 12 weeks post-transplantation, mice in all
HFD sham groups were glucose intolerant compared with
LFD controls, regardless of the drug treatment used (Fig-
ure 7A). As expected based on our previous cohort, we
found no effect of the cell therapy on glucose tolerance
at 12 weeks post-transplantation in the HFD-fed mice
without drug treatment (Figure 7B), and likewise, the com-
bination with rosiglitazone was also ineffective at this time
(Figure 7E). Interestingly, the cell therapy significantly
improved glucose tolerance at 12 weeks post-transplanta-
tion when combined with either metformin (Figure 7C)
or sitagliptin (Figure 7D) treatment. In fact, glycemic con-
trol during an oral glucose challenge was indistinguishable
between the LFD controls and HFD-fed mice receiving
sitagliptin with the cell therapy, with the exception of a
marginally higher peak glucose level at 15 min post-gavage
(Figure 7D). The improved glucose tolerance in cell
transplant recipients from the metformin- and sitagliptin-
treated groups was associated with significantly reduced
fastingmouse C-peptide levels compared with their respec-
tive sham controls at 16 weeks post-transplantation
(Figure 7G), an effect that was not yet evident at 4 weeks
(Figure 7F). Interestingly, the improvements in glucose
tolerance were not associated with differences in glucose-
stimulated C-peptide secretion by hESC-derived grafts. All
transplant recipients showed robust glucose-responsive hu-
man C-peptide secretion at 16 weeks, and there were no
differences in human C-peptide levels between HFD-fed
mice treated with different antidiabetic drugs (Figure 7H).100%) for each animal as the baseline. For clarity, all glucose curves
y for each diet group. See Figure S4 for glucose curves combined on
as box-and-whisker plots showing individual mice as separate data
10% sham; #p < 0.05, two-tailed t test (Tx versus sham). For all line
ong-term body weight and blood glucose tracking, and Figure S5 for
circulating leptin levels.
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Figure 6. Diet-Induced Obesity Was Reversed Following Progenitor Cell Transplantation Combined with an Antidiabetic Drug
(A–F) Fasting body weight was assessed in mice fed a 10% fat diet without drug (black/gray; all panels; n = 8 mice), 60% fat diet without
drug (A and B, blue; n = 7–8 mice per group), 60% fat diet plus metformin (A and C, purple; n = 7–8 mice per group), 60% fat diet plus
sitagliptin (A and D, orange; n = 8 mice per group), or 60% fat diet plus rosiglitazone (A and E, green; n = 8 mice per group). Body weight
tracking for sham mice from all treatment groups is shown in (A). Sham mice (solid lines, closed symbols) and transplant recipients (Tx;
dashed lines, open symbols) from each treatment group are shown together with the LFD control as a reference (B–E). The change in body
weight from day 2 to day 12 is shown in box-and-whisker plots to the right of each line graph, with each data point representing an
individual mouse. Data on line graphs are represented as mean ± SEM. (F) Body weight pre-transplant (day 2) and post-transplantation
(day 75).
(legend continued on next page)
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DISCUSSION
Our first goal in these studies was to establish an immuno-
deficient mouse model of hyperglycemia associated with
insulin resistance and obesity that would resemble a type
2 diabetes phenotype. It was not feasible to transplant
human progenitor cells into traditional models of type 2
diabetes, such as db/db or ob/obmice, because macroencap-
sulation devices are unlikely to protect human cells from
xenograft immune rejection (Brauker et al., 1996; Mcken-
zie et al., 2001). Although macroencapsulation was not
required to protect the cells in immunodeficient mice,
we opted to transplant within immunoisolation devices
so that our findings would be more clinically relevant
(macroencapsulated hESC-derived progenitor cells are
currently being evaluated in patients with diabetes by Via-
Cyte [ClinicalTrials.gov, Identifier: NCT02239354]). We
used SCID-beige mice for our studies because the matura-
tion of hESC-derived pancreatic progenitor cells has been
well characterized in this strain (Rezania et al., 2012,
2013; Bruin et al., 2013). SCID-beige mice fed 45%–60%
fat diets had many characteristics of type 2 diabetes,
including increased BW and adiposity, fasting hyperglyce-
mia, and glucose intolerance, insulin resistance, hyperlep-
tinemia, and hepatic lipidosis. However, unlike humans
with type 2 diabetes, mice fed 45% or 60% fat diets had
reduced circulating free fatty acid and triglyceride levels.
We speculate that excess lipids are likely taken up by pe-
ripheral tissues, whichmay explain the severe ectopic lipid
deposition observed in the liver and kidneys of these mice.
Western-diet-fed mice were similar with respect to glucose
intolerance and hepatic/kidney lipidosis, but showed
a more mild phenotype in terms of obesity, fasting hyper-
glycemia, insulin resistance, and leptin levels. We also
observed pancreatic beta cell dysfunction in the 60% fat
and Western-diet groups, as indicated by the lack of
glucose-stimulated insulin secretion. Therefore, although
no one diet produced a phenotype that perfectly modeled
the human condition, all three HFDs resulted in character-
istics that mirrored important features of type 2 diabetes,
most notably including hyperglycemia associated with
obesity and insulin resistance. The mechanism underlying
the rapid HFD-induced metabolic dysregulation in mice
lacking T cells, B cells, and fully functioning macrophages
remains to be determined and is intriguing given that
immune cells reportedly play a central role in the develop-(G and H) Epididymal fat pad weight relative to body weight (G) an
transplantation.
(A–E) *p < 0.05, one-way ANOVA for comparisons of all groups (LFD ve
#p < 0.05, one-way ANOVA for comparison of each group to LFD contro
phenotype of mice on HFDs in cohort 2 (pre-transplant) and Figure S
drugs with or without cell transplants.
Stemment of obesity-associated inflammation and subsequent
insulin resistance (Feuerer et al., 2009; Nishimura et al.,
2009; Winer et al., 2009, 2011). Notably, in contrast to
ob/obmice, we did not observe infiltration of F4/80-positive
macrophages in the epididymal fat tissue of HFD-fed
SCID-beige mice, suggesting that other mechanisms may
be involved in the development of insulin resistance in
this animal model.
Transplantation of human pancreatic progenitor cells
into HFD-fed mice resulted in improved glycemic control
over time. At 12 weeks post-transplantation, mice on
45%–60% fat diets andwith hESC-derived grafts had signif-
icantly lower HbA1C levels than sham mice on the same
diet, indicative of improved long-term glycemic control,
although these mice remained glucose intolerant at
18 weeks. As the progenitor cells matured over time, circu-
lating human C-peptide levels increased, engrafted cells
became glucose/arginine responsive, and significant im-
provements were observed in glucose excursions following
mixed-meal and glucose challenges in HFD transplant re-
cipients compared with HFD shams between 20 and
24 weeks post-transplantation. We suspect that the addi-
tion of an alternative source of appropriately regulated in-
sulin secretion provided sufficient compensation for pe-
ripheral insulin resistance, a feat that the endogenous
pancreas was incapable of achieving on its own. Transplan-
tation did not affect the pancreatic beta cell mass, so it
is unlikely that expansion of the endogenous pancreas
contributed to the observed improvements in glucose ho-
meostasis in HFD-fed mice. Interestingly, transplant recip-
ients from the 45%–60% diet group had enhanced insulin
sensitivity compared with shams, which may also have
contributed to their improved glucose tolerance. An im-
provement in insulin sensitivity as a result of higher circu-
lating insulin levels is counterintuitive, but consistent with
previous reports in patients with type 1 diabetes following
human islet transplantation (Rickels et al., 2013) and pa-
tients with type 2 diabetes following short-term intensive
insulin therapy (Kramer et al., 2013).
Based on these data, we predicted that co-treating HFD
transplant recipients with antidiabetic drugs, particularly
insulin sensitizers, would improve the efficacy of the
progenitor cell therapy. Although co-treatment with met-
formin, an insulin sensitizer from the biguanide class,
improved BW and glucose intolerance after just 12 weeks,
the combination with rosiglitazone, an insulin sensitizerd plasma mouse leptin levels (H) were assessed at 20 weeks post-
rsus HFD Sham, LFD versus HFD Tx, HFD Sham versus HFD Tx); (F–H)
l; *p < 0.05, two-tailed t test, Tx versus Sham. See Figure S6 for the
7 for long-term blood glucose tracking following administration of
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Figure 7. The Combination of Either Sitagliptin or Metformin with a Cell Transplant Resulted in Improved Glucose Tolerance within
12 Weeks
(A–E) OGTTs were performed at 12 weeks post-transplantation in mice fed a 10% fat diet without drug (black/gray; all panels; Sham: n = 5
mice), 60% fat diet without drug (A and B, blue; Tx/Sham: n = 7 mice), 60% fat diet plus metformin (A and C, purple; Tx/Sham: n = 5 mice),
60% fat diet plus sitagliptin (A and D, orange; Tx: n = 7 mice, Sham: n = 8 mice), or 60% fat diet plus rosiglitazone (A and E, green; Tx: n = 7
mice, Sham: n = 6 mice). Blood glucose levels for sham mice from all treatment groups are shown together in (A). Sham mice (solid lines,
closed symbols) and transplant recipients (Tx; dashed lines, open symbols) from each treatment group are shown together with LFD
controls as a reference (B–E). The area under the curve (AUC) is shown in box-and-whisker plots to the right of each line graph, with
separate data points representing individual mice. Data on line graphs are represented as mean ± SEM. (A) *p < 0.05 (one-way ANOVA
versus LFD).
(legend continued on next page)
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from the TZD class, did not reverse hyperglycemia. Interest-
ingly, the most effective antidiabetic drug tested in our
study was the DPP4 inhibitor sitagliptin, which acts to in-
crease circulating incretin levels by preventing inactivation
by DPP4. When sitagliptin was combined with the cell
therapy, HFD-fed mice had glucose tolerance and BW
that was similar to LFD-fed control mice at 12 weeks post-
transplantation. Furthermore, transplanted mice on either
sitagliptin or metformin had reduced fasting mouse
C-peptide levels, which may suggest that the endogenous
pancreas has been relieved of the demand to compensate
for insulin resistance. The reversal of hyperleptinemia in
both sitagliptin- and metformin-treated transplant recipi-
ents also suggests a more robust reversal of the obesity
phenotype in these groups as compared with the HFD
transplant recipients treated with rosiglitazone or without
drugs. Taken together, our data suggest that a cell-based in-
sulin replacement therapy could be considered as a future
treatment option for type 2 diabetes, particularly if com-
bined with antidiabetic drugs.
Many of the same pathways that trigger obesity-associ-
ated beta cell dysfunction in patients with type 2 diabetes
may also contribute to graft failure following islet trans-
plantation (Potter et al., 2014). Therefore, a potential
caveat in replacing dysfunctional beta cells with healthy
insulin-secreting cells is the risk of subsequent graft failure
in an obesogenic and hyperglycemic host environment.
Indeed, in previous studies, both human and rodent islet
grafts displayed beta cell dysfunction following exposure
to HFDs (Hiramatsu and Grill, 2001; Gargani et al., 2013)
and chronic hyperglycemia (Eizirik et al., 1997; Biarne´s
et al., 2002). In contrast, the development of hESC-derived
pancreatic progenitor cells into insulin-secreting cells
was accelerated by exposure to chronic hyperglycemia
compared to normoglycemia (Bruin et al., 2013). However,
the potential effect of an obesogenic environment on
hESC-derived progenitor cells was not previously exam-
ined. We also demonstrated previously that short-term
exposure to exendin-4, a GLP-1 mimetic, for 4 weeks
post-transplantation did not affect the development of
progenitor cells (Bruin et al., 2013), but the possible effects
of long-term treatment with antidiabetic medications has
not been reported. In the current studies there was a ten-
dency for increased basal glucagon levels and arginine-
induced human insulin secretion in HFD-fed compared
with LFD-fed transplant recipients, but overall the results(B–E) For glucose curves, two-way ANOVA was used to examine differen
LFD; #p < 0.05, HFD Tx versus LFD). For the AUC, one-way ANOVA was us
Sham versus HFD Tx; *p < 0.05; ns, not significant).
(F and G) Fasting mouse C-peptide levels at 4 weeks (F) or 16 weeks (G)
(H) Human C-peptide levels were measured after an overnight fast an
paired two-tailed t test (0 versus 60 min).
Stemshowed that neither an obesogenic environment nor expo-
sure to antidiabetic drugs had a major impact on the
function of hESC-derived insulin-secreting cells in vivo.
However, there are several important caveats to our immu-
nocompromised mouse model that should be considered:
first, we cannot exclude the possibility that HFDs or antidi-
abetic drugs may impact the function of hESC-derived
endocrine cells in an immunocompetent host environ-
ment; second, human progenitor cells may respond differ-
ently to mouse versus human diabetogenic/obesogenic
stimuli; and third, the potential long-term impact of
HFDs or antidiabetic drugs on hESC-derived grafts cannot
be examined in mice because of their relatively short life-
span. Regardless, hESC-derived cells secreted similar levels
of humanC-peptide in response to secretagogue challenges
in all diet groups (with or without antidiabetic drugs),
and qPCR demonstrated no significant differences in
expression of several islet-related genes within grafts from
different diet or drug treatment groups. The only sign
that an obesogenic environment may have impacted pro-
genitor cell maturation was a small but significant increase
in the percentage of insulin/glucagon bihormonal cells
in grafts from mice fed 45%–60% fat versus 10% fat diets.
These cells may represent a subpopulation of immature,
fetal-like endocrine cells (Riedel et al., 2012; Bruin et al.,
2014), but without conducting lineage-tracing studies,
we cannot know their source or fate. Regardless, the ability
of hESC-derived progenitor cells to thrive and mature into
functional pancreatic endocrine cells in a chronic obeso-
genic and hyperglycemic (albeit immunocompromised)
environment further supports the feasibility of a stem
cell-based therapy for type 2 diabetes.
In our previous studies, a dose of 5 million progenitor
cells was sufficient to normalize hyperglycemia in mice
with severe insulin deficiency caused by streptozotocin-
induced beta cell destruction (Rezania et al., 2012, 2013;
Bruin et al., 2013). With diet-induced hyperglycemia, the
same dose of progenitor cells generated higher levels of hu-
man C-peptide, yet the graft-derived insulin (combined
with endogenous mouse insulin) was insufficient to
completely normalize glycemia. Therefore, it is likely that
a larger mass of insulin-producing cells would be required
to ameliorate hyperglycemia in insulin-resistant patients
with type 2 diabetes compared with insulin-deficient pa-
tients with type 1 diabetes. Alternatively, our studies also
suggest that a progenitor-based cell therapy may be moreces at each time point during the OGTT (*p < 0.05, HFD Sham versus
ed compare all groups (LFD versus HFD Sham, LFD versus HFD Tx, HFD
post-transplantation. *p < 0.05, two-tailed t test (Tx versus Sham).
d 60 min following an intraperitoneal glucose challenge. *p < 0.05,
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effective in a type 2 diabetic setting if it is combined with
an antidiabetic drug. These findings are in line with
another report by our lab, in which leptin therapy was
shown to enhance the performance of transplanted islets
in diabeticmice (Denroche et al., 2013), likely due to the in-
sulin-sensitizing effects of leptin (Denroche et al., 2011).
Conclusions
In conclusion, we have demonstrated that hESC-derived
pancreatic progenitor cells may be a feasible option for
treating patients with type 2 diabetes, in addition to those
with type 1 diabetes. Our data suggest that transplanted
hESC-derived insulin-producing cells thrive following
chronic exposure to HFDs, at least in immunodeficient
mice. Thus, stem cells are a candidate for restoring func-
tional beta cells in an insulin-resistant, obese setting.EXPERIMENTAL PROCEDURES
In Vitro Differentiation of hESCs and Assessment of
Pancreatic Progenitor Cells
TheH1hESC linewas obtained from theWiCell Research Institute.
All experiments at the University of British Columbia (UBC) with
H1 cells were approved by the Canadian StemCell Oversight Com-
mittee and the UBCClinical Research Ethics Board. Pluripotent H1
cells were differentiated into pancreatic progenitor cells according
to our 14-day, four-stage protocol as previously described (Bruin
et al., 2013). Expression of key pancreatic progenitor cell markers
was assessed prior to transplantation using custom Taqman
qPCR Arrays (Applied Biosystems) and flow cytometry as described
in Supplemental Experimental Procedures.
Animals
Male SCID-beige mice (C.B-Igh-1b/GbmsTac-Prkdcscid-LystbgN7,
8–10 weeks old; Taconic) weremaintained on a 12 hr light/dark cy-
cle throughout the study. All experiments were approved by the
UBC Animal Care Committee and carried out in accordance with
the Canadian Council on Animal Care guidelines.
Diets and Drug Administration
All mice were given ad libitum access to a standard irradiated diet
(Harlan Laboratories, Teklad Diet #2918) for 2 weeks to allow for
acclimatization following their arrival at UBC. In the first cohort,
micewereplacedononeof fourdifferentdiet regimens (ResearchDi-
ets) for the 36-week study (n = 11per diet): (1) ‘‘10% fat’’ control diet
(D12450K, 10 kcal% fat, 70 kcal% carbohydrate [no sucrose]), (2)
‘‘45% fat’’ diet (D12451, 45 kcal% fat [primarily lard], 35 kcal% car-
bohydrate), (3) ‘‘60%fat’’ diet (D12492, 60kcal% fat [primarily lard],
20 kcal% carbohydrate), or (4) ‘‘Western’’ diet (D12079B, 41 kcal%
fat [primarily milk fat], 43 kcal% carbohydrate [primarily sucrose]).
In the second cohort, mice were placed on either the 10% fat
control diet (D12450K; n = 8) for the duration of the study or
60% fat diet (D12492; n = 64) for 6 weeks, followed by one of
the following treatment regimens for the remainder of the study
(n = 16 per group): (1) 60% fat diet with no drug (D12492),618 Stem Cell Reports j Vol. 4 j 605–620 j April 14, 2015 j ª2015 The Autho(2) 60% fat diet containing rosiglitazone (18 mg/kg diet or
3 mg/kg BW per day; Cayman Chemical; Research Diets custom
diet formulation D08121002), (3) 60% fat diet containing sitaglip-
tin (4 g/kg diet or 750 mg/kg BW per day; sitagliptin phosphate
monohydrate, BioVision; Research Diets custom diet formula-
tion D08062502R), or (4) 60% fat diet (D12492) and metfor-
min (1,1-dimethylbiguanide hydrochloride) in drinking water
(1.25 mg/ml or 250 mg/kg BW per day).
Transplantation of hESC-Derived Pancreatic
Progenitor Cells
The procedure used for transplantation of macro-encapsulated
pancreatic progenitor cells is described in Supplemental Experi-
mental Procedures. In the first cohort, mice were randomly as-
signed to receive either a cell transplant (Tx, n = 7 per diet) or
sham surgery (sham, n = 4 per diet) after 7 weeks of LFD or HFD
feeding. In the second cohort, HFD-fed mice (+/ drug treatment)
received either a transplant (n = 8 per group) or sham surgery (n = 8
per group) 1 week after administration of the antidiabetic drugs.
LFD controls all received sham surgery. The treatment groups are
summarized in Table S2.
Metabolic Assessments
All metabolic analyses were performed in conscious, restrained
mice and blood samples were collected via the saphenous vein.
BW and blood glucose levels were assessed regularly throughout
each study following a 4-hr morning fast. For all other metabolic
tests, blood was collected after fasting (time 0) and at the indicated
time points following administration of various secretagogues. De-
tails about the fasting time, route of administration, and dose used
for eachmetabolic test are provided in Supplemental Experimental
Procedures along with information about the assays used to mea-
sure circulating hormones, lipids, and HbA1C levels.
Dual-Energy X-Ray Absorptiometry
Body composition was determined using dual-energy X-ray ab-
sorptiometry (DEXA) with a PIXImus Mouse Densitometer (Inside
Outside Sales). Data are expressed as % fat.
qRT-PCR
Theracyte devices were harvested at 29 weeks post-transplantation
from cohort 1 and stored for qPCR analysis. Details regarding the
qPCR analysis, human islet donors, and the procedure used to
isolate RNA from engrafted tissue are described in Supplemental
Experimental Procedures. Primers are listed in Table S3.
Immunofluorescent Staining and Image
Quantification
Prior to transplantation, a portion of differentiated pancreatic pro-
genitor cells were fixed overnight in 4% paraformaldehyde (PFA)
and then embedded in 1% agarose prior to paraffin embedding.
In cohort 1, the Theractye devices and a variety of tissues (listed
in Table S1) were harvested at 29 weeks post-transplantation,
fixed in 4% PFA, and stored in 70% EtOH prior to paraffin embed-
ding. All paraffin sections (5 mm thick) were prepared by Wax-it
Histology Services. Immunofluorescent staining was performedrs
as previously described (Rezania et al., 2011) and details about the
primary antibodies are provided in Table S4. The procedures used
for image analysis and quantification are described in Supple-
mental Experimental Procedures. H&E staining was performed ac-
cording to standard procedures and tissue analysis was performed
in a blinded fashion by an independent pathologist (Nova Pathol-
ogy PC).
Statistical Analysis
All statistical analyses were performed using GraphPad Prism soft-
ware (GraphPad Software). Details about specific statistical tests are
described in Supplemental Experimental Procedures. For all ana-
lyses, p < 0.05 was considered statistically significant. Data are pre-
sented as themean ± SEM (line graphs) or as box-and-whisker plots
showing individual data points.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, seven figures, and five tables and can be found with
this article online at http://dx.doi.org/10.1016/j.stemcr.2015.02.
011.
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